Brokerages expect Stealth BioTherapeutics Corp (NASDAQ:MITO) to announce ($0.04) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Stealth BioTherapeutics’ earnings. The company is expected to issue its next earnings report on Thursday, April 2nd.
On average, analysts expect that Stealth BioTherapeutics will report full-year earnings of ($0.30) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.25). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.22) to ($0.11). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last announced its quarterly earnings data on Thursday, November 14th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04).
Stealth BioTherapeutics stock remained flat at $$3.08 on Wednesday. The company’s stock had a trading volume of 209,078 shares, compared to its average volume of 302,757. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.40 and a current ratio of 1.40. The stock has a market capitalization of $107.89 million and a price-to-earnings ratio of -2.18. The firm has a 50-day moving average of $6.90 and a two-hundred day moving average of $8.48. Stealth BioTherapeutics has a fifty-two week low of $2.73 and a fifty-two week high of $20.99.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.